We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$46B
AUM Growth
-$5.82B
(-11%)
Cap. Flow
+$1.91B
Cap. Flow
% of AUM
4.16%
Top 10 Holdings %
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$127M |
| 2 |
Cigna
CI
|
+$54M |
| 3 |
CVS Health
CVS
|
+$38.8M |
| 4 |
Marathon Petroleum
MPC
|
+$28.9M |
| 5 |
Diamondback Energy
FANG
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$124M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$100M |
| 3 |
PX
Praxair Inc
PX
|
+$80.2M |
| 4 |
COL
Rockwell Collins
COL
|
+$43.7M |
| 5 |
ANDV
Andeavor
ANDV
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.95% |
| 2 | Financials | 15.85% |
| 3 | Healthcare | 14.41% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Industrials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Flotek Industries
FTK
$1.3B
| $84K | ﹤0.01% |
12,770
-10,615
| -45% | -$107K |
|
|
TTPH
2902
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $82K | ﹤0.01% |
3,649
+1,055
| +41% | +$41.3K |
|
|
GEN
2903
DELISTED
Genesis Healthcare, Inc.
GEN
| $81K | ﹤0.01% |
68,297
+23,160
| +51% | +$34.4K |
|
|
CLD
2904
DELISTED
Cloud Peak Energy Inc
CLD
| $81K | ﹤0.01% |
220,124
+34,938
| +19% | +$49.8K |
|
|
LLEX
2905
DELISTED
Lilis Energy, Inc. Common Stock
LLEX
| $81K | ﹤0.01% |
59,039
+19,274
| +48% | +$52.2K |
|
|
ALNA
2906
DELISTED
Allena Pharmaceuticals
ALNA
| $78K | ﹤0.01% |
+14,349
| New | +$124K |
|
2907
Nokia
NOK
$53.5B
| $77K | ﹤0.01% |
13,300
+772
| +6% | +$4.33K |
|
|
TBIO
2908
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $77K | ﹤0.01% |
+10,315
| New | +$75.6K |
|
|
ELGX
2909
DELISTED
Endologix Inc
ELGX
| $77K | ﹤0.01% |
10,698
+3,070
| +40% | +$34.2K |
|
|
TLGT
2910
DELISTED
Teligent, Inc
TLGT
| $76K | ﹤0.01% |
5,539
+1,779
| +47% | +$46.5K |
|
2911
KALA BIO
KALA
$13.6M
| $75K | ﹤0.01% |
+6
| New | +$104K |
|
|
IO
2912
DELISTED
ION Geophysical Corporation
IO
| $75K | ﹤0.01% |
+14,506
| New | +$147K |
|
2913
Asure Software
ASUR
$248M
| $73K | ﹤0.01% |
+14,433
| New | +$119K |
|
2914
NCS Multistage Holdings
NCSM
$124M
| $73K | ﹤0.01% |
+715
| New | +$137K |
|
|
FNM
2915
DELISTED
FANNIE MAE
FNM
| $72K | ﹤0.01% |
68,075
| – | – |
|
2916
Aegon
AEG
$14B
| $71K | ﹤0.01% |
17,855
+689
| +4% | +$3.36K |
|
|
BGFV
2917
DELISTED
Big 5 Sporting Goods
BGFV
| $71K | ﹤0.01% |
27,566
-22,068
| -44% | -$87.7K |
|
2918
NextDecade
NEXT
$1.71B
| $70K | ﹤0.01% |
+12,915
| New | +$65.2K |
|
2919
Valhi
VHI
$408M
| $68K | ﹤0.01% |
2,918
+854
| +41% | +$21.4K |
|
2920
Corvus Pharmaceuticals
CRVS
$1.17B
| $67K | ﹤0.01% |
18,203
+5,570
| +44% | +$38K |
|
|
MRSN
2921
DELISTED
Mersana Therapeutics
MRSN
| $66K | ﹤0.01% |
644
+204
| +46% | +$32.3K |
|
2922
Smart Sand
SND
$180M
| $65K | ﹤0.01% |
29,222
+7,700
| +36% | +$24.3K |
|
|
JNCE
2923
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $65K | ﹤0.01% |
19,151
+5,410
| +39% | +$25.3K |
|
2924
Cartesian Therapeutics
RNAC
$245M
| $63K | ﹤0.01% |
793
+265
| +50% | +$60.5K |
|
|
FRE
2925
DELISTED
FREDDIE MAC D/B/A VOTING
FRE
| $63K | ﹤0.01% |
58,983
| – | – |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.
- RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
- RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
- RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
- RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
- RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
- RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.